Reply to thread

Based on yesterday's call with Tad I wouldn't say it's out of the question if Alcon buys Xiidra. Clearly something more is going to happen. You don't just pull MSLs, TLL MDAs (i.e. resources/budget) for a non-priority drug and think that's it. Mark my words the other shoe will drop in the next few months